Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children

Phase 4 Completed 130 enrolled Murdoch Childrens Research Institute Monash Health · collab Royal Children's Hospital · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

MIST+ is studying a nasal spray to see if it will reduce the need for surgery for snoring. Children aged 3-12 are invited to take part. Snoring affects up to 10% of children and can cause sleeping problems and concentration or behavioural issues in the daytime. Currently the most common treatment for snoring is surgery to remove the tonsils and/or adenoids, however many children wait a long time to see a specialist. This research is trying to find if nasal sprays can help children with snoring, and whether this can reduce the need for surgery.

Timeline

Start: 2022-12-05
Primary completion: 2025-07-17
Completion: 2025-07-17

Outcome

Missed primary endpoint

paper with no evidence for a clinically significant difference between groups (risk difference, -0.9%; 95% CI, -20.7% to 19.0%; P = .93). PMID 41557344 ↗

paper with no added benefit from INS. PMID 41557344 ↗

Publications

Nixon GM, Anderson D, Baker A, Davidson A, Griffiths A, Grobler AC, Pinczower G, Rimmer J, Rose E, Selman CJ, Simpson CM, Vandeleur M, Perrett KP. Intranasal Treatments for Children With Sleep-Disordered Breathing: The MIST+ Randomized Clinical Trial. JAMA Pediatr. 2026 Mar 1;180(3):240-249. doi: 10.1001/jamapediatrics.2025.5717.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mometasone furoate	Other / unclassified	50 ug	Intranasal